Thus, to the best of our knowledge, this is the first time that an enhanced TGF-β expression and bioactivity has been reported in the serum of a severe OI pediatric patient when compared to a moderate OI one. This evidence concerns the gene TGFB1 and osteogenesis imperfecta.